Cellectis (XPAR:ALCLS) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALCLS Cellectis SA XPAR:ALCLS
56 GF Score
Price €1.31
GF Value €2.74
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cellectis Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cellectis  (XPAR:ALCLS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cellectis Cyclically Adjusted PB Ratio Related Terms


Cellectis Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Cellectis's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis Cyclically Adjusted PB Ratio Chart

Cellectis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.32 0.34 0.45 0.26 0.78

Cellectis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.39 0.73 0.50 0.47

XPAR:ALCLS vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Cellectis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cellectis's Cyclically Adjusted PB Ratio falls into.


XPAR:ALCLS
56GF Score
Cellectis SA XPAR:ALCLS
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectis Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cellectis's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Cellectis's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.357/123.5000*123.5000
=0.357

Current CPI (Jun. 2026) = 123.5000.

Cellectis Quarterly Data

Book Value per Share CPI Adj_Book
201609 7.219 100.340 8.885
201612 7.374 100.650 9.048
201703 7.186 101.170 8.772
201706 6.617 101.320 8.066
201709 7.066 101.330 8.612
201712 6.622 101.850 8.030
201803 6.239 102.750 7.499
201806 9.873 103.370 11.796
201809 9.564 103.560 11.406
201812 9.283 103.470 11.080
201903 9.074 103.890 10.787
201906 8.381 104.580 9.897
201909 8.250 104.500 9.750
201912 7.457 104.980 8.773
202003 7.953 104.590 9.391
202006 7.231 104.790 8.522
202009 6.548 104.550 7.735
202012 5.900 104.960 6.942
202103 5.728 105.750 6.689
202106 5.608 106.340 6.513
202109 4.974 106.810 5.751
202112 4.572 107.850 5.235
202203 4.012 110.490 4.484
202206 3.794 112.550 4.163
202209 3.262 112.740 3.573
202212 2.584 114.160 2.795
202303 1.995 116.790 2.110
202306 1.592 117.650 1.671
202309 1.294 118.260 1.351
202312 1.069 118.390 1.115
202403 1.169 119.470 1.208
202406 1.385 120.200 1.423
202409 1.159 119.560 1.197
202412 1.264 119.950 1.301
202503 1.073 120.380 1.101
202506 0.825 121.360 0.840
202509 0.852 120.950 0.870
202512 0.644 120.890 0.658
202603 0.517 122.410 0.522
202606 0.357 123.500 0.357

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Cellectis (XPAR:ALCLS) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be undervalued. The current stock price of €1.31 is trading 52.2% below its estimated GF Value™ of €2.74. GuruFocus considers Cellectis to be Possible Value Trap.

Key valuation signals for XPAR:ALCLS:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €2.74 vs. price of €1.31 (52.2% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALCLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
56GF Score

Get the complete analysis for XPAR:ALCLS

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price
€2.74
GF Value